Protective effects of etanercept and methylprednisolone on pancreatic damage in cerulein-induced acute pancreatitis.
OBJECTIVE
To examine the pharmacological effect of etanercept and methylprednisolone (MP) on acute pancreatitis (AP) induced by cerulein in an experimental rat model.


METHODS
The present study was carried out in the Experimental Research Center, Ondokuz Mayis University, Samsun, Turkey between December 2008 and October 2009. Forty adult Sprague-Dawley rats were divided into 5 groups (n=8): 1--sham, 2--cerulein induced pancreatitis (over 20 hours), 3--etanercept (5 mg/kg, intraperitoneal), 4--MP (10 mg/kg, intramuscular), 5--etanercept plus MP. The rats in groups 3, 4, and 5 were cerulein-induced pancreatitis at 20 hours, as well. After the treatment, the pancreas and blood were taken for histopathological and biochemical analysis.


RESULTS
All cerulein-treated rats developed biochemical and histopathological AP after 20 hours. Histological findings of pancreatitis and serum levels of amylase and lipase were lower in group 5 compared to group 2. Pancreatic inflammation and total pathological score were statistically reduced in the tissues of the pancreas at 20 hours after the treatment of etanercept plus MP in group 5 compared to groups 2, 3, and 4.


CONCLUSIONS
In the early stage of cerulein induced AP, the administration of etanercept plus MP attenuated pancreatic inflammation and significant damage in rats.
Kilic
Erol
E
Department of Surgery, School of Medicine, Ondokuz Mayis University, Samsun, Turkey.
Amanvermez
Ramazan
R
Kefeli
Mehmet
M
Polat
Cafer
C
Gunay
Murat
M
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002108:Ceruletide; D004359:Drug Therapy, Combination; D000068800:Etanercept; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000627:therapeutic use*; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use*; D010195:Pancreatitis / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage / Q000627:therapeutic use*
D000893:Anti-Inflammatory Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D002108:Ceruletide; D000068800:Etanercept; D008775:Methylprednisolone